These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36184867)

  • 1. Allopurinol for gout: Consider the case for limited
    Tse T; Wu B; Vagholkar S; Willcock S
    Aust J Gen Pract; 2022 Oct; 51(10):813-814. PubMed ID: 36184867
    [No Abstract]   [Full Text] [Related]  

  • 2. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
    Cheng H; Yan D; Zuo X; Liu J; Liu W; Zhang Y
    Pharmacogenet Genomics; 2018 May; 28(5):117-124. PubMed ID: 29642234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
    Teng GG; Tan-Koi WC; Dong D; Sung C
    Pharmacogenomics; 2020 Mar; 21(4):279-291. PubMed ID: 32180492
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
    Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
    J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenetic considerations in the treatment of gout.
    Roberts RL; Stamp LK
    Pharmacogenomics; 2015; 16(6):619-29. PubMed ID: 25876828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenine phosphoribosyltransferase deficiency in a Chinese man with early-onset gout.
    Chen CJ; Schumacher HR
    J Rheumatol; 2009 May; 36(5):1090-1. PubMed ID: 19435978
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
    Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
    Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic advances in gout: potential applications in clinical practice.
    Tai V; Merriman TR; Dalbeth N
    Curr Opin Rheumatol; 2019 Mar; 31(2):144-151. PubMed ID: 30575597
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
    J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
    Dainichi T; Uchi H; Moroi Y; Furue M
    Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
    Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
    Plumpton CO; Alfirevic A; Pirmohamed M; Hughes DA
    Rheumatology (Oxford); 2017 Oct; 56(10):1729-1739. PubMed ID: 28957559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
    Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
    Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profile of anti-gout agents: an update.
    Stamp LK
    Curr Opin Rheumatol; 2014 Mar; 26(2):162-8. PubMed ID: 24378930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The devil bites his joints--severe tophaceous gout.
    Tausche AK
    J Clin Rheumatol; 2012 Oct; 18(7):375. PubMed ID: 23047539
    [No Abstract]   [Full Text] [Related]  

  • 19. Gout.
    Br Med J; 1974 Mar; 1(5905):446-8. PubMed ID: 4816858
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.